25 XP   0   0   10

Oncolytics Biotech Inc
Buy, Hold or Sell?

Let's analyse Oncolytics Biotech Inc together

PenkeI guess you are interested in Oncolytics Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Oncolytics Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Oncolytics Biotech Inc

I send you an email if I find something interesting about Oncolytics Biotech Inc.

Quick analysis of Oncolytics Biotech Inc (30 sec.)










What can you expect buying and holding a share of Oncolytics Biotech Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.27
Expected worth in 1 year
$0.28
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.02
Return On Investment
1.6%

For what price can you sell your share?

Current Price per Share
$1.06
Expected price per share
$0.97 - $1.395
How sure are you?
50%

1. Valuation of Oncolytics Biotech Inc (5 min.)




Live pricePrice per Share (EOD)

$1.06

Intrinsic Value Per Share

$-2.08 - $-1.82

Total Value Per Share

$-1.81 - $-1.55

2. Growth of Oncolytics Biotech Inc (5 min.)




Is Oncolytics Biotech Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$20m$21.7m-$2.7m-14.7%

How much money is Oncolytics Biotech Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.9m-$4.2m-$744.1k-14.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Oncolytics Biotech Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#588 / 1016

Most Revenue
#723 / 1016

Most Profit
#423 / 1016

Most Efficient
#167 / 1016

What can you expect buying and holding a share of Oncolytics Biotech Inc? (5 min.)

Welcome investor! Oncolytics Biotech Inc's management wants to use your money to grow the business. In return you get a share of Oncolytics Biotech Inc.

What can you expect buying and holding a share of Oncolytics Biotech Inc?

First you should know what it really means to hold a share of Oncolytics Biotech Inc. And how you can make/lose money.

Speculation

The Price per Share of Oncolytics Biotech Inc is $1.06. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oncolytics Biotech Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oncolytics Biotech Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.27. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oncolytics Biotech Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.04-3.6%-0.07-6.2%-0.06-5.6%-0.06-6.1%-0.06-5.4%
Usd Book Value Change Per Share-0.01-1.3%0.000.4%-0.02-2.4%0.011.0%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-1.3%0.000.4%-0.02-2.4%0.011.0%0.000.1%
Usd Price Per Share1.35-1.83-1.36-1.95-1.50-
Price to Earnings Ratio-8.87--7.19--5.85--2.63--4.53-
Price-to-Total Gains Ratio-96.33--46.60--73.45--40.42--32.75-
Price to Book Ratio5.09-7.47-4.79--218.86--104.42-
Price-to-Total Gains Ratio-96.33--46.60--73.45--40.42--32.75-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.06
Number of shares943
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.000.01
Gains per Quarter (943 shares)4.119.70
Gains per Year (943 shares)16.4638.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1016603929
20332207868
3049380116107
4066540155146
5082700194185
6099860233224
701151020272263
801321180311302
901481340349341
1001651500388380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%2.094.00.02.1%
Book Value Change Per Share1.02.01.025.0%3.08.01.025.0%6.013.01.030.0%10.029.01.025.0%29.063.04.030.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.096.00.0%
Total Gains per Share1.02.01.025.0%3.08.01.025.0%6.013.01.030.0%10.029.01.025.0%29.063.04.030.2%

Fundamentals of Oncolytics Biotech Inc

About Oncolytics Biotech Inc

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Fundamental data was last updated by Penke on 2024-04-11 16:56:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Oncolytics Biotech Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Oncolytics Biotech Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oncolytics Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Oncolytics Biotech Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • -10.2% Return on Assets means that Oncolytics Biotech Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oncolytics Biotech Inc:

  • The MRQ is -10.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -18.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.2%TTM-18.1%+7.9%
TTM-18.1%YOY-14.7%-3.4%
TTM-18.1%5Y-21.7%+3.6%
5Y-21.7%10Y-21.6%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.2%-13.5%+3.3%
TTM-18.1%-12.9%-5.2%
YOY-14.7%-11.8%-2.9%
5Y-21.7%-14.1%-7.6%
10Y-21.6%-16.0%-5.6%
1.1.3. Return on Equity

Shows how efficient Oncolytics Biotech Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • -14.3% Return on Equity means Oncolytics Biotech Inc generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oncolytics Biotech Inc:

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-26.4%+12.1%
TTM-26.4%YOY-19.5%-7.0%
TTM-26.4%5Y-33.5%+7.1%
5Y-33.5%10Y-33.9%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-16.9%+2.6%
TTM-26.4%-16.1%-10.3%
YOY-19.5%-15.1%-4.4%
5Y-33.5%-19.9%-13.6%
10Y-33.9%-20.9%-13.0%

1.2. Operating Efficiency of Oncolytics Biotech Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Oncolytics Biotech Inc is operating .

  • Measures how much profit Oncolytics Biotech Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oncolytics Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y--625.6%+625.6%
1.2.2. Operating Ratio

Measures how efficient Oncolytics Biotech Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Oncolytics Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y-7.894-7.894

1.3. Liquidity of Oncolytics Biotech Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Oncolytics Biotech Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.01 means the company has $9.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Oncolytics Biotech Inc:

  • The MRQ is 9.009. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.776. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.009TTM9.776-0.766
TTM9.776YOY14.437-4.661
TTM9.7765Y11.316-1.540
5Y11.31610Y8.655+2.661
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0093.914+5.095
TTM9.7764.220+5.556
YOY14.4375.388+9.049
5Y11.3166.045+5.271
10Y8.6556.406+2.249
1.3.2. Quick Ratio

Measures if Oncolytics Biotech Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.04 means the company can pay off $9.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oncolytics Biotech Inc:

  • The MRQ is 9.041. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.757. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.041TTM7.757+1.284
TTM7.757YOY14.477-6.721
TTM7.7575Y10.392-2.635
5Y10.39210Y8.296+2.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0413.572+5.469
TTM7.7573.998+3.759
YOY14.4775.390+9.087
5Y10.3925.969+4.423
10Y8.2966.287+2.009

1.4. Solvency of Oncolytics Biotech Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Oncolytics Biotech Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oncolytics Biotech Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Oncolytics Biotech Inc assets are financed with 29.0% credit (debt) and the remaining percentage (100% - 29.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oncolytics Biotech Inc:

  • The MRQ is 0.290. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.309. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.290TTM0.309-0.019
TTM0.309YOY0.247+0.062
TTM0.3095Y0.371-0.062
5Y0.37110Y0.318+0.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2900.336-0.046
TTM0.3090.334-0.025
YOY0.2470.269-0.022
5Y0.3710.366+0.005
10Y0.3180.390-0.072
1.4.2. Debt to Equity Ratio

Measures if Oncolytics Biotech Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.8% means that company has $0.41 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oncolytics Biotech Inc:

  • The MRQ is 0.408. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.451. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.408TTM0.451-0.043
TTM0.451YOY0.330+0.121
TTM0.4515Y0.725-0.273
5Y0.72510Y0.604+0.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4080.382+0.026
TTM0.4510.396+0.055
YOY0.3300.335-0.005
5Y0.7250.434+0.291
10Y0.6040.465+0.139

2. Market Valuation of Oncolytics Biotech Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Oncolytics Biotech Inc generates.

  • Above 15 is considered overpriced but always compare Oncolytics Biotech Inc to the Biotechnology industry mean.
  • A PE ratio of -8.87 means the investor is paying $-8.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oncolytics Biotech Inc:

  • The EOD is -6.967. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.874. Based on the earnings, the company is expensive. -2
  • The TTM is -7.186. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.967MRQ-8.874+1.906
MRQ-8.874TTM-7.186-1.688
TTM-7.186YOY-5.847-1.340
TTM-7.1865Y-2.630-4.556
5Y-2.63010Y-4.531+1.902
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.967-2.259-4.708
MRQ-8.874-2.569-6.305
TTM-7.186-2.664-4.522
YOY-5.847-4.120-1.727
5Y-2.630-6.258+3.628
10Y-4.531-6.171+1.640
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oncolytics Biotech Inc:

  • The EOD is -4.491. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.719. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.763. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.491MRQ-5.719+1.229
MRQ-5.719TTM-6.763+1.044
TTM-6.763YOY-5.802-0.961
TTM-6.7635Y-8.829+2.066
5Y-8.82910Y-0.500-8.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.491-2.924-1.567
MRQ-5.719-3.246-2.473
TTM-6.763-3.488-3.275
YOY-5.802-5.620-0.182
5Y-8.829-8.315-0.514
10Y-0.500-8.826+8.326
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Oncolytics Biotech Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.09 means the investor is paying $5.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Oncolytics Biotech Inc:

  • The EOD is 3.993. Based on the equity, the company is fair priced.
  • The MRQ is 5.085. Based on the equity, the company is overpriced. -1
  • The TTM is 7.466. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.993MRQ5.085-1.092
MRQ5.085TTM7.466-2.380
TTM7.466YOY4.791+2.675
TTM7.4665Y-218.859+226.325
5Y-218.85910Y-104.424-114.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.9931.851+2.142
MRQ5.0852.090+2.995
TTM7.4662.095+5.371
YOY4.7912.844+1.947
5Y-218.8593.466-222.325
10Y-104.4243.815-108.239
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Oncolytics Biotech Inc.

3.1. Institutions holding Oncolytics Biotech Inc

Institutions are holding 6.985% of the shares of Oncolytics Biotech Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Anson Funds Management LP5.05740.63673814299-1487737-28.0597
2023-12-31Morgan Stanley - Brokerage Accounts0.30680231385168891270.2515
2023-12-31International Assets Investment Management, LLC0.26490.0343199777-1676-0.832
2023-12-31Millennium Management LLC0.16950.0001127842-85181-39.9868
2023-12-31Advisor Resource Council0.13260.01571000001000000
2023-12-31CIBC World Markets Inc.0.08070.000260887-26-0.0427
2023-12-31Commonwealth Equity Services Inc0.07370.000155580555800
2023-12-31Royal Bank of Canada0.0728054925-804-1.4427
2023-12-31Geode Capital Management, LLC0.055604194200
2023-12-31Long Focus Capital Management, LLC0.0530.00184000000
2023-12-31Bank of Montreal0.0498037582493715.1233
2023-12-31BMO Capital Markets Corp.0.0498037582493715.1233
2023-12-31Susquehanna International Group, LLP0.0402030306303060
2023-12-31Ausdal Financial Partners Inc0.03980.005300001000050
2023-12-31Brave Asset Management Inc0.03310.00962500000
2023-12-31TWO SIGMA SECURITIES, LLC0.0310.000323378233780
2023-12-31Newman Dignan & Sheerar Inc0.02920.00922015220150
2023-12-31LPL Financial Corp0.026019579-2000-9.2683
2023-12-31C2P Capital Advisory Group LLC dba Prosperity Capital Advisors0.01990.002215000150000
2023-12-31Banque Cantonale Vaudoise0.01580.00071190000
Total 6.60160.71574978979-1142380-22.9%

3.2. Funds holding Oncolytics Biotech Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-29iShares S&P/TSX Small Cap ETF0.06230.04974695200
2024-02-29Fidelity Nasdaq Composite Index0.05560.00034194200
2024-02-29Vifag 2002 SICAV0.03980.05353000000
Total 0.15770.103511889400.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Oncolytics Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0140.004-421%-0.025+78%0.010-236%0.001-1188%
Book Value Per Share--0.2650.252+5%0.289-8%0.241+10%0.195+36%
Current Ratio--9.0099.776-8%14.437-38%11.316-20%8.655+4%
Debt To Asset Ratio--0.2900.309-6%0.247+17%0.371-22%0.318-9%
Debt To Equity Ratio--0.4080.451-10%0.330+24%0.725-44%0.604-32%
Dividend Per Share----0%-0%-0%-0%
Eps---0.038-0.066+74%-0.060+57%-0.065+70%-0.057+50%
Free Cash Flow Per Share---0.059-0.069+16%-0.061+3%-0.057-3%-0.046-21%
Free Cash Flow To Equity Per Share---0.0420.009-596%-0.033-22%0.009-564%0.001-4287%
Gross Profit Margin--1.0001.000+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---1.817--------
Intrinsic Value_10Y_min---2.078--------
Intrinsic Value_1Y_max---0.186--------
Intrinsic Value_1Y_min---0.241--------
Intrinsic Value_3Y_max---0.555--------
Intrinsic Value_3Y_min---0.699--------
Intrinsic Value_5Y_max---0.921--------
Intrinsic Value_5Y_min---1.128--------
Market Cap79944988.000-27%101816730.000138206783.500-26%102759477.500-1%147296000.697-31%113184379.355-10%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio3.993-27%5.0857.466-32%4.791+6%-218.859+4404%-104.424+2153%
Pe Ratio-6.967+21%-8.874-7.186-19%-5.847-34%-2.630-70%-4.531-49%
Price Per Share1.060-27%1.3501.833-26%1.363-1%1.953-31%1.501-10%
Price To Free Cash Flow Ratio-4.491+21%-5.719-6.763+18%-5.802+1%-8.829+54%-0.500-91%
Price To Total Gains Ratio-75.640+21%-96.334-46.603-52%-73.447-24%-40.421-58%-32.747-66%
Quick Ratio--9.0417.757+17%14.477-38%10.392-13%8.296+9%
Return On Assets---0.102-0.181+78%-0.147+44%-0.217+113%-0.216+113%
Return On Equity---0.143-0.264+84%-0.195+36%-0.335+134%-0.339+136%
Total Gains Per Share---0.0140.004-421%-0.025+78%0.010-236%0.001-1188%
Usd Book Value--20021763.20018990093.600+5%21780325.118-8%18176348.976+10%14737780.979+36%
Usd Book Value Change Per Share---0.0140.004-421%-0.025+78%0.010-236%0.001-1188%
Usd Book Value Per Share--0.2650.252+5%0.289-8%0.241+10%0.195+36%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.038-0.066+74%-0.060+57%-0.065+70%-0.057+50%
Usd Free Cash Flow---4450652.800-5167609.600+16%-4595601.562+3%-4303807.699-3%-3504800.786-21%
Usd Free Cash Flow Per Share---0.059-0.069+16%-0.061+3%-0.057-3%-0.046-21%
Usd Free Cash Flow To Equity Per Share---0.0420.009-596%-0.033-22%0.009-564%0.001-4287%
Usd Market Cap79944988.000-27%101816730.000138206783.500-26%102759477.500-1%147296000.697-31%113184379.355-10%
Usd Price Per Share1.060-27%1.3501.833-26%1.363-1%1.953-31%1.501-10%
Usd Profit---2868553.600-4980016.800+74%-4235889.553+48%-4818959.646+68%-3864756.575+35%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.0140.004-421%-0.025+78%0.010-236%0.001-1188%
 EOD+3 -5MRQTTM+18 -12YOY+15 -155Y+13 -1710Y+16 -14

4.2. Fundamental Score

Let's check the fundamental score of Oncolytics Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.967
Price to Book Ratio (EOD)Between0-13.993
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.041
Current Ratio (MRQ)Greater than19.009
Debt to Asset Ratio (MRQ)Less than10.290
Debt to Equity Ratio (MRQ)Less than10.408
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.102
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Oncolytics Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.187
Ma 20Greater thanMa 501.084
Ma 50Greater thanMa 1001.064
Ma 100Greater thanMa 2001.172
OpenGreater thanClose1.030
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets38,820
Total Liabilities11,257
Total Stockholder Equity27,563
 As reported
Total Liabilities 11,257
Total Stockholder Equity+ 27,563
Total Assets = 38,820

Assets

Total Assets38,820
Total Current Assets38,173
Long-term Assets647
Total Current Assets
Cash And Cash Equivalents 31,534
Short-term Investments 3,378
Net Receivables 15
Other Current Assets 3,246
Total Current Assets  (as reported)38,173
Total Current Assets  (calculated)38,173
+/-0
Long-term Assets
Property Plant Equipment 647
Long-term Assets Other 0
Long-term Assets  (as reported)647
Long-term Assets  (calculated)647
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,237
Long-term Liabilities7,020
Total Stockholder Equity27,563
Total Current Liabilities
Short-term Debt 133
Accounts payable 1,082
Other Current Liabilities 4,104
Total Current Liabilities  (as reported)4,237
Total Current Liabilities  (calculated)5,319
+/- 1,082
Long-term Liabilities
Capital Lease Obligations 423
Long-term Liabilities  (as reported)7,020
Long-term Liabilities  (calculated)423
+/- 6,597
Total Stockholder Equity
Common Stock430,906
Retained Earnings -446,003
Accumulated Other Comprehensive Income 544
Other Stockholders Equity 42,116
Total Stockholder Equity (as reported)27,563
Total Stockholder Equity (calculated)27,563
+/-0
Other
Capital Stock430,906
Cash and Short Term Investments 34,912
Common Stock Shares Outstanding 73,731
Current Deferred Revenue-1,082
Liabilities and Stockholders Equity 38,820
Net Debt -31,111
Net Invested Capital 27,563
Net Working Capital 33,936
Property Plant and Equipment Gross 1,342
Short Long Term Debt Total 423



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
21,405
21,196
22,767
21,658
20,945
20,723
19,999
19,073
19,073
19,468
17,331
17,968
17,968
18,815
21,531
26,051
25,435
31,221
29,471
39,489
40,519
38,081
40,114
46,294
43,660
40,828
37,980
33,566
41,775
37,700
33,897
30,782
30,782
19,011
13,542
13,987
9,802
12,755
10,240
35,593
30,159
26,569
21,137
44,432
54,945
49,690
43,053
36,025
47,372
36,989
29,086
22,078
44,272
39,267
32,549
28,222
23,036
20,047
18,079
17,193
31,445
33,190
31,001
27,384
23,023
21,368
18,437
14,758
10,623
17,579
14,848
18,150
14,127
20,693
18,150
14,865
16,461
15,302
16,285
19,658
34,553
34,604
31,242
34,346
54,180
56,309
52,593
45,880
44,446
40,239
38,959
35,328
35,328
31,966
46,089
38,820
38,82046,08931,96635,32835,32838,95940,23944,44645,88052,59356,30954,18034,34631,24234,60434,55319,65816,28515,30216,46114,86518,15020,69314,12718,15014,84817,57910,62314,75818,43721,36823,02327,38431,00133,19031,44517,19318,07920,04723,03628,22232,54939,26744,27222,07829,08636,98947,37236,02543,05349,69054,94544,43221,13726,56930,15935,59310,24012,7559,80213,98713,54219,01130,78230,78233,89737,70041,77533,56637,98040,82843,66046,29440,11438,08140,51939,48929,47131,22125,43526,05121,53118,81517,96817,96817,33119,46819,07319,07319,99920,72320,94521,65822,76721,19621,405
   > Total Current Assets 
17,611
17,302
18,903
17,796
17,111
16,830
16,036
15,090
15,090
10,201
7,949
8,445
8,445
13,695
16,267
20,974
20,490
26,153
24,258
34,217
35,170
32,798
33,923
40,994
38,332
35,553
32,765
28,336
36,514
32,378
28,642
25,554
25,554
18,413
13,036
13,543
9,462
12,521
10,021
34,701
29,278
25,663
20,238
43,470
53,985
49,461
42,783
35,633
46,976
36,561
28,659
21,669
43,872
38,761
31,981
27,690
22,527
19,576
17,535
16,668
30,949
32,722
30,557
26,924
22,611
20,995
18,103
14,438
10,322
17,223
14,505
17,817
13,771
20,320
17,721
14,453
15,386
14,344
15,438
18,930
33,905
34,078
30,517
33,736
53,356
55,439
51,593
44,904
43,536
39,407
38,205
34,261
34,261
30,995
45,337
38,173
38,17345,33730,99534,26134,26138,20539,40743,53644,90451,59355,43953,35633,73630,51734,07833,90518,93015,43814,34415,38614,45317,72120,32013,77117,81714,50517,22310,32214,43818,10320,99522,61126,92430,55732,72230,94916,66817,53519,57622,52727,69031,98138,76143,87221,66928,65936,56146,97635,63342,78349,46153,98543,47020,23825,66329,27834,70110,02112,5219,46213,54313,03618,41325,55425,55428,64232,37836,51428,33632,76535,55338,33240,99433,92332,79835,17034,21724,25826,15320,49020,97416,26713,6958,4458,4457,94910,20115,09015,09016,03616,83017,11117,79618,90317,30217,611
       Cash And Cash Equivalents 
17,566
17,165
18,761
17,619
16,955
16,635
15,858
14,971
14,971
9,964
7,746
8,319
8,319
13,486
3,813
2,641
2,941
3,059
2,501
12,409
8,464
7,911
4,695
3,511
6,442
7,224
3,957
3,492
11,325
6,924
3,326
6,715
6,715
8,179
12,680
7,430
7,366
11,983
9,655
32,449
27,143
23,206
16,098
39,297
49,913
46,640
40,243
32,919
44,622
33,803
26,007
19,324
41,520
36,153
29,472
25,220
20,156
16,881
15,013
14,153
28,578
30,018
27,962
24,016
20,233
18,321
15,613
12,034
10,102
16,676
14,034
11,836
7,745
18,741
16,214
13,700
14,214
12,276
12,299
14,148
30,567
29,911
26,711
31,220
50,362
50,799
48,087
41,262
39,483
33,689
32,362
15,872
15,872
17,520
39,981
31,534
31,53439,98117,52015,87215,87232,36233,68939,48341,26248,08750,79950,36231,22026,71129,91130,56714,14812,29912,27614,21413,70016,21418,7417,74511,83614,03416,67610,10212,03415,61318,32120,23324,01627,96230,01828,57814,15315,01316,88120,15625,22029,47236,15341,52019,32426,00733,80344,62232,91940,24346,64049,91339,29716,09823,20627,14332,4499,65511,9837,3667,43012,6808,1796,7156,7153,3266,92411,3253,4923,9577,2246,4423,5114,6957,9118,46412,4092,5013,0592,9412,6413,81313,4868,3198,3197,7469,96414,97114,97115,85816,63516,95517,61918,76117,16517,566
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,029
18,112
17,357
22,464
21,305
21,511
26,249
24,063
28,065
36,895
31,244
27,277
27,538
24,122
24,356
24,609
24,865
18,499
18,499
9,751
0
5,847
1,926
0
0
1,680
1,680
1,680
3,610
3,609
3,609
1,929
1,929
1,937
1,969
1,969
1,969
1,969
2,002
2,002
2,002
2,002
2,032
2,032
2,032
2,032
2,061
2,061
2,061
2,061
2,089
2,089
2,089
2,089
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,721
2,412
13,798
13,798
6,831
3,723
3,378
3,3783,7236,83113,79813,7982,4121,7210000000000000000000002,0892,0892,0892,0892,0612,0612,0612,0612,0322,0322,0322,0322,0022,0022,0022,0021,9691,9691,9691,9691,9371,9291,9293,6093,6093,6101,6801,6801,680001,9265,84709,75118,49918,49924,86524,60924,35624,12227,53827,27731,24436,89528,06524,06326,24921,51121,30522,46417,35718,11212,02900000000000000
       Net Receivables 
30
126
108
138
127
127
133
95
95
48
76
49
49
59
251
64
62
64
49
48
41
68
56
47
117
54
38
84
51
47
37
80
80
47
48
86
68
103
59
65
33
59
31
285
73
51
78
55
53
90
90
45
78
47
35
106
44
54
85
192
46
61
53
340
60
55
45
54
36
62
33
4,805
4,939
90
57
52
52
44
458
2,069
127
56
70
90
112
136
251
866
102
356
497
730
0
559
630
15
1563055907304973561028662511361129070561272,06945844525257904,9394,80533623654455560340536146192855444106354778459090535578517328531593365591036886484780803747518438541174756684148496462642515949497648959513312712713810812630
       Other Current Assets 
15
11
34
39
29
68
45
0
0
190
0
77
77
150
173
0
129
566
404
250
416
0
0
0
528
998
0
639
0
798
414
260
260
436
308
180
101
435
307
507
422
718
499
279
390
840
533
722
332
699
593
331
273
559
471
362
296
610
405
292
265
581
481
507
229
530
357
261
183
485
438
1,176
1,087
0
1,450
701
1,121
2,024
2,681
2,714
3,210
4,111
3,736
2,427
2,882
4,504
3,255
2,776
3,950
5,363
5,346
3,861
0
6,085
4,726
3,246
3,2464,7266,08503,8615,3465,3633,9502,7763,2554,5042,8822,4273,7364,1113,2102,7142,6812,0241,1217011,45001,0871,176438485183261357530229507481581265292405610296362471559273331593699332722533840390279499718422507307435101180308436260260414798063909985280004162504045661290173150777701900045682939341115
   > Long-term Assets 
3,794
3,894
3,864
3,862
3,834
3,893
3,963
3,982
3,982
9,267
9,382
9,523
9,523
5,119
5,264
5,077
4,946
5,068
5,213
5,271
5,349
5,283
6,191
5,300
5,329
5,275
5,216
5,229
5,261
5,322
5,255
5,228
5,228
598
507
445
340
233
219
892
881
906
899
963
961
229
270
392
396
428
427
409
400
506
569
532
509
470
544
525
496
468
443
460
412
373
334
320
302
355
343
333
356
373
429
413
1,075
958
847
727
647
526
725
609
825
870
1,000
976
911
832
754
1,067
1,067
971
752
647
6477529711,0671,0677548329119761,0008708256097255266477278479581,0754134293733563333433553023203343734124604434684965255444705095325695064004094274283963922702299619638999068818922192333404455075985,2285,2285,2555,3225,2615,2295,2165,2755,3295,3006,1915,2835,3495,2715,2135,0684,9465,0775,2645,1199,5239,5239,3829,2673,9823,9823,9633,8933,8343,8623,8643,8943,794
       Property Plant Equipment 
3,794
3,894
3,864
59
3,834
3,893
3,963
211
211
4,303
4,416
309
309
4,822
4,967
291
4,918
5,043
5,201
5,259
5,349
5,283
6,191
190
179
157
152
150
174
168
169
201
201
236
236
264
250
233
219
208
197
222
215
227
225
229
270
392
396
428
427
409
400
506
569
532
509
470
544
525
496
468
443
460
412
373
334
320
302
355
343
333
356
373
429
413
1,075
958
847
727
647
526
725
609
825
870
1,000
976
911
832
754
840
840
744
752
647
6477527448408407548329119761,0008708256097255266477278479581,0754134293733563333433553023203343734124604434684965255444705095325695064004094274283963922702292252272152221972082192332502642362362012011691681741501521571791906,1915,2835,3495,2595,2015,0434,9182914,9674,8223093094,4164,3032112113,9633,8933,834593,8643,8943,794
       Intangible Assets 
0
0
0
3,803
0
0
0
3,771
3,771
0
0
4,208
4,208
0
0
4,675
0
0
0
4,155
0
0
0
4,383
4,408
5,118
5,063
4,357
4,397
5,154
5,130
5,027
5,027
362
271
181
90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000901812713625,0275,0275,1305,1544,3974,3575,0635,1184,4084,3830004,1550004,675004,2084,208003,7713,7710003,803000
       Other Assets 
0
0
0
2,549
0
0
0
2,369
0
3,274
3,129
5,859
0
221
220
3,691
21
19
0
4,165
0
0
0
4,383
4,408
0
4,538
4,357
0
4,879
5,130
5,044
4,879
355
0
148
71
0
0
650
674
642
665
737
758
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000758737665642674650007114803554,8795,0445,1304,87904,3574,53804,4084,3830004,165019213,69122022105,8593,1293,27402,3690002,549000
> Total Liabilities 
1,389
2,461
2,439
1,743
1,500
1,976
3,218
3,119
3,119
1,235
1,054
1,410
1,410
812
1,011
1,035
2,146
1,068
1,524
1,099
1,417
1,693
1,835
1,842
2,166
2,057
2,514
2,766
2,849
2,376
2,298
2,821
2,821
4,146
2,801
4,534
4,274
3,228
3,116
4,227
2,933
3,640
1,810
2,501
2,339
4,186
3,478
6,504
6,072
5,303
6,711
7,291
5,625
5,424
4,913
6,009
4,833
3,667
3,299
3,374
4,275
3,058
3,276
2,709
2,554
2,781
2,809
4,069
3,349
3,311
2,782
9,867
9,384
9,727
9,100
8,670
10,761
11,514
12,834
19,766
11,121
10,615
10,271
9,593
9,511
9,823
9,881
9,781
9,431
9,466
10,562
9,577
9,577
9,727
17,071
11,257
11,25717,0719,7279,5779,57710,5629,4669,4319,7819,8819,8239,5119,59310,27110,61511,12119,76612,83411,51410,7618,6709,1009,7279,3849,8672,7823,3113,3494,0692,8092,7812,5542,7093,2763,0584,2753,3743,2993,6674,8336,0094,9135,4245,6257,2916,7115,3036,0726,5043,4784,1862,3392,5011,8103,6402,9334,2273,1163,2284,2744,5342,8014,1462,8212,8212,2982,3762,8492,7662,5142,0572,1661,8421,8351,6931,4171,0991,5241,0682,1461,0351,0118121,4101,4101,0541,2353,1193,1193,2181,9761,5001,7432,4392,4611,389
   > Total Current Liabilities 
124
1,196
1,217
605
389
893
2,162
2,321
2,321
761
742
1,260
1,260
662
861
885
1,996
918
1,374
949
1,267
1,543
1,660
1,692
2,016
1,907
2,364
2,616
2,849
2,376
2,298
2,821
2,821
4,146
2,801
4,534
4,274
3,228
3,116
4,227
2,933
3,640
1,810
2,501
2,339
4,186
3,478
6,504
6,072
5,303
6,711
7,291
5,625
5,424
4,913
6,009
4,833
3,667
3,299
3,374
4,275
3,058
3,276
2,709
2,554
2,781
2,809
4,069
3,349
3,311
2,782
5,230
4,129
3,924
3,243
2,815
4,538
4,467
4,084
12,869
4,297
3,868
3,357
2,709
2,409
2,582
2,709
2,690
2,424
2,544
3,666
2,469
2,469
2,651
10,018
4,237
4,23710,0182,6512,4692,4693,6662,5442,4242,6902,7092,5822,4092,7093,3573,8684,29712,8694,0844,4674,5382,8153,2433,9244,1295,2302,7823,3113,3494,0692,8092,7812,5542,7093,2763,0584,2753,3743,2993,6674,8336,0094,9135,4245,6257,2916,7115,3036,0726,5043,4784,1862,3392,5011,8103,6402,9334,2273,1163,2284,2744,5342,8014,1462,8212,8212,2982,3762,8492,6162,3641,9072,0161,6921,6601,5431,2679491,3749181,9968858616621,2601,2607427612,3212,3212,1628933896051,2171,196124
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,546
-927
-927
0
0
359
373
358
340
344
308
332
249
252
234
269
294
307
330
295
189
0
133
191
133
133191133018929533030729426923425224933230834434035837335900-927-927-1,54600000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
359
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000003590000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
56
1,196
1,217
605
389
893
2,162
2,321
2,321
761
742
1,260
1,260
662
861
885
1,996
918
1,374
949
1,267
1,543
1,660
1,692
2,016
1,907
2,364
2,616
2,849
2,376
2,298
2,821
2,821
4,146
2,801
3,726
3,389
2,776
2,914
4,018
2,889
3,418
1,759
2,508
2,411
4,345
3,312
6,378
6,128
5,215
6,832
7,291
5,625
5,424
4,913
6,009
4,833
3,667
2,946
3,374
4,275
3,058
3,276
2,709
2,554
2,781
2,809
4,069
3,349
3,311
2,782
3,684
3,201
2,996
2,240
1,826
3,232
4,094
3,725
3,173
2,778
2,687
2,279
1,805
1,919
2,194
2,334
1,988
2,048
2
3
1
0
629
2,187
1,082
1,0822,18762901322,0481,9882,3342,1941,9191,8052,2792,6872,7783,1733,7254,0943,2321,8262,2402,9963,2013,6842,7823,3113,3494,0692,8092,7812,5542,7093,2763,0584,2753,3742,9463,6674,8336,0094,9135,4245,6257,2916,8325,2156,1286,3783,3124,3452,4112,5081,7593,4182,8894,0182,9142,7763,3893,7262,8014,1462,8212,8212,2982,3762,8492,6162,3641,9072,0161,6921,6601,5431,2679491,3749181,9968858616621,2601,2607427612,3212,3212,1628933896051,2171,19656
       Other Current Liabilities 
69
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,534
4,274
3,228
3,116
4,227
2,933
3,640
1,810
2,501
2,339
4,186
3,478
6,504
6,072
5,303
6,711
0
0
0
0
0
0
0
3,299
0
0
0
0
0
0
0
0
0
0
0
0
1,546
927
927
77
61
20
4,094
3,725
12,529
3,953
3,560
3,024
2,460
2,156
2,348
2,440
2,396
2,117
2,214
3,371
2,280
48
153
5,291
4,104
4,1045,291153482,2803,3712,2142,1172,3962,4402,3482,1562,4603,0243,5603,95312,5293,7254,0942061779279271,5460000000000003,29900000006,7115,3036,0726,5043,4784,1862,3392,5011,8103,6402,9334,2273,1163,2284,2744,534000000000000000000000000000000000069
   > Long-term Liabilities 
1,265
1,265
1,221
1,138
1,111
1,084
1,056
798
798
474
312
150
150
150
150
150
150
150
150
150
150
150
174
150
150
150
150
150
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,637
5,255
5,803
5,857
5,855
6,223
7,047
8,750
6,897
6,824
6,748
6,914
6,883
7,102
7,241
7,172
7,091
7,007
6,922
6,896
7,108
7,108
7,076
7,053
7,020
7,0207,0537,0767,1087,1086,8966,9227,0077,0917,1727,2417,1026,8836,9146,7486,8246,8978,7507,0476,2235,8555,8575,8035,2554,63700000000000000000000000000000000000000000001501501501501501741501501501501501501501501501501503124747987981,0561,0841,1111,1381,2211,2651,265
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
420
317
246
166
93
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000931662463174200000000000000000000000000000000000000000000000000000000000000000000000000000
       Long term Debt 
104
101
99
101
95
99
95
94
94
99
95
95
102
111
111
116
115
113
119
125
124
122
128
129
128
134
134
129
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
420
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000420000000000000000000000000000000000000000000000000129134134128129128122124125119113115116111111102959599949495999510199101104
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,546
927
927
0
0
420
317
246
166
93
17
184
153
372
510
442
361
277
192
166
184
567
346
323
290
2903233465671841661922773614425103721531841793166246317420009279271,54600000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,695
5,255
5,803
5,857
2,308
5,803
6,730
8,504
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
6,730
0
0
0
0
00006,7306,7306,7306,7306,7306,7306,7306,7306,7306,7306,7306,7306,7308,5046,7305,8032,3085,8575,8035,2553,69500000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
420
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004200000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
20,016
18,735
20,329
19,915
19,445
18,746
16,781
15,954
15,954
18,233
16,278
16,558
16,558
18,003
20,520
25,016
23,290
30,152
27,947
38,389
39,102
36,388
38,280
44,452
41,494
38,771
35,466
30,799
38,926
35,324
31,599
27,961
27,961
14,865
10,742
9,453
5,528
9,527
7,124
31,366
27,226
22,930
19,327
41,932
52,606
45,504
39,575
29,520
41,299
31,686
22,375
14,787
38,647
33,843
27,636
22,213
18,202
16,379
14,780
13,819
27,170
30,131
27,724
24,674
20,469
18,587
15,628
10,690
7,275
14,268
12,066
8,284
4,743
10,967
9,049
6,195
5,700
3,788
3,451
-108
23,432
23,989
20,971
24,753
44,670
46,487
42,712
36,099
35,015
30,773
28,397
25,751
25,751
22,239
29,018
27,563
27,56329,01822,23925,75125,75128,39730,77335,01536,09942,71246,48744,67024,75320,97123,98923,432-1083,4513,7885,7006,1959,04910,9674,7438,28412,06614,2687,27510,69015,62818,58720,46924,67427,72430,13127,17013,81914,78016,37918,20222,21327,63633,84338,64714,78722,37531,68641,29929,52039,57545,50452,60641,93219,32722,93027,22631,3667,1249,5275,5289,45310,74214,86527,96127,96131,59935,32438,92630,79935,46638,77141,49444,45238,28036,38839,10238,38927,94730,15223,29025,01620,52018,00316,55816,55816,27818,23315,95415,95416,78118,74619,44519,91520,32918,73520,016
   Common Stock
12,670
12,397
14,245
14,480
14,006
15,062
23,285
14,958
14,901
18,798
17,982
19,270
20,810
27,254
29,284
34,475
34,944
40,731
43,769
55,398
57,924
57,731
60,884
72,334
72,191
75,722
75,900
71,261
80,146
87,759
93,504
93,067
90,401
90,843
87,140
78,267
75,540
87,894
95,897
125,388
129,907
123,972
128,260
155,695
182,588
183,910
168,785
173,858
197,372
194,658
201,619
198,155
228,502
228,514
228,514
228,613
229,801
232,304
235,040
237,657
254,220
261,016
261,230
261,325
261,224
261,976
262,218
262,322
262,311
270,091
270,900
271,710
272,230
282,459
283,742
285,193
289,432
292,611
295,556
311,078
333,789
341,150
344,816
356,824
382,963
391,125
391,167
391,348
396,504
396,807
398,068
409,412
0
413,424
428,826
430,906
430,906428,826413,4240409,412398,068396,807396,504391,348391,167391,125382,963356,824344,816341,150333,789311,078295,556292,611289,432285,193283,742282,459272,230271,710270,900270,091262,311262,322262,218261,976261,224261,325261,230261,016254,220237,657235,040232,304229,801228,613228,514228,514228,502198,155201,619194,658197,372173,858168,785183,910182,588155,695128,260123,972129,907125,38895,89787,89475,54078,26787,14090,84390,40193,06793,50487,75980,14671,26175,90075,72272,19172,33460,88457,73157,92455,39843,76940,73134,94434,47529,28427,25420,81019,27017,98218,79814,90114,95823,28515,06214,00614,48014,24512,39712,670
   Retained Earnings -446,003-442,054-432,129-424,688-424,688-409,696-405,289-400,194-393,416-385,664-380,792-373,546-367,111-357,783-351,034-344,207-344,606-325,205-321,676-316,422-311,483-306,664-303,328-299,117-294,446-289,701-286,696-282,347-278,829-273,619-270,287-267,706-263,689-260,192-257,368-253,518-249,966-246,187-241,551-236,832-231,347-225,555-219,441-214,421-207,814-199,322-190,078-179,899-171,441-159,764-153,531-146,367-138,762-131,290-127,281-122,929-118,788-113,543-110,849-106,514-102,557-97,796-93,655-80,522-80,522-76,437-72,673-68,993-65,030-60,140-56,715-53,727-50,733-54,346-43,282-40,328-37,951-33,959-30,863-27,671-24,995-23,299-21,520-16,451-16,451-14,908-12,918-10,359-10,359-9,003-6,558-5,202-4,188-3,676-2,118-844
   Accumulated Other Comprehensive Income 
2,500
2,500
2,500
2,500
0
2,500
-10
2,500
2,500
2,650
2,650
2,703
2,703
2,815
4,205
5,298
5,195
6,720
6,665
9,697
9,382
8,921
10,366
4,430
4,430
4,217
4,217
4,217
6,655
6,655
6,655
5,346
5,346
5,346
5,346
-386
0
0
0
-451
0
0
0
-514
-194
-195
-128
-118
-152
-36
-83
-57
-23
51
17
80
61
88
188
280
506
465
657
761
591
460
493
554
533
489
362
374
444
508
459
608
548
483
521
464
759
613
545
400
360
312
406
388
341
453
723
659
0
554
655
544
54465555406597234533413884063123604005456137594645214835486084595084443743624895335544934605917616574655062801888861801751-23-57-83-36-152-118-128-195-194-514000-451000-3865,3465,3465,3465,3466,6556,6556,6554,2174,2174,2174,4304,43010,3668,9219,3829,6976,6656,7205,1955,2984,2052,8152,7032,7032,6502,6502,5002,500-102,50002,5002,5002,5002,500
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,567
32,142
32,370
32,579
32,956
33,090
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000033,09032,95632,57932,37032,14212,567000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-403
Gross Profit-403-403
 
Operating Income (+$)
Gross Profit-403
Operating Expense-33,388
Operating Income-33,791-33,791
 
Operating Expense (+$)
Research Development17,709
Selling General Administrative15,554
Selling And Marketing Expenses0
Operating Expense33,38833,263
 
Net Interest Income (+$)
Interest Income1,151
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,151
 
Pretax Income (+$)
Operating Income-33,791
Net Interest Income1,151
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-27,655-39,927
EBIT - interestExpense = -33,791
-27,655
-27,752
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-33,791-27,655
Earnings Before Interest and Taxes (EBITDA)-33,388
 
After tax Income (+$)
Income Before Tax-27,655
Tax Provision-111
Net Income From Continuing Ops-32,357-27,766
Net Income-27,752
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses33,791
Total Other Income/Expenses Net6,136-1,151
 

Technical Analysis of Oncolytics Biotech Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oncolytics Biotech Inc. The general trend of Oncolytics Biotech Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oncolytics Biotech Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oncolytics Biotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.29 < 1.3103 < 1.395.

The bearish price targets are: 1 > 0.97 > 0.97.

Tweet this
Oncolytics Biotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oncolytics Biotech Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oncolytics Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oncolytics Biotech Inc. The current macd is 0.00057249.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oncolytics Biotech Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Oncolytics Biotech Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Oncolytics Biotech Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Oncolytics Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartOncolytics Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oncolytics Biotech Inc. The current adx is 15.54.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Oncolytics Biotech Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Oncolytics Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oncolytics Biotech Inc. The current sar is 1.02.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Oncolytics Biotech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oncolytics Biotech Inc. The current rsi is 47.19. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Oncolytics Biotech Inc Daily Relative Strength Index (RSI) ChartOncolytics Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oncolytics Biotech Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Oncolytics Biotech Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Oncolytics Biotech Inc Daily Stochastic Oscillator ChartOncolytics Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oncolytics Biotech Inc. The current cci is -42.44982333.

Oncolytics Biotech Inc Daily Commodity Channel Index (CCI) ChartOncolytics Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oncolytics Biotech Inc. The current cmo is -10.07744553.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Oncolytics Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartOncolytics Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oncolytics Biotech Inc. The current willr is -82.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Oncolytics Biotech Inc Daily Williams %R ChartOncolytics Biotech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oncolytics Biotech Inc.

Oncolytics Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oncolytics Biotech Inc. The current atr is 0.07044547.

Oncolytics Biotech Inc Daily Average True Range (ATR) ChartOncolytics Biotech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oncolytics Biotech Inc. The current obv is 2,175,194.

Oncolytics Biotech Inc Daily On-Balance Volume (OBV) ChartOncolytics Biotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oncolytics Biotech Inc. The current mfi is 39.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Oncolytics Biotech Inc Daily Money Flow Index (MFI) ChartOncolytics Biotech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oncolytics Biotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Oncolytics Biotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oncolytics Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.187
Ma 20Greater thanMa 501.084
Ma 50Greater thanMa 1001.064
Ma 100Greater thanMa 2001.172
OpenGreater thanClose1.030
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Oncolytics Biotech Inc with someone you think should read this too:
  • Are you bullish or bearish on Oncolytics Biotech Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oncolytics Biotech Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oncolytics Biotech Inc

I send you an email if I find something interesting about Oncolytics Biotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Oncolytics Biotech Inc.

Receive notifications about Oncolytics Biotech Inc in your mailbox!